BOSTON–(BUSINESS WIRE)–Elucid Bioimaging Inc. (“Elucid Bio”) today announced that vascuCAP, Elucid Bio’s AI-enabled software for evaluating atherosclerotic plaque stability from CTA, has been added to the IBM Imaging AI Marketplace, an IBM Watson Health® solution. The IBM Imaging AI Marketplace provides […]
Tag: Elucid Bio
Study Demonstrates that AI Technology is Better Predictor of Stroke than Traditional Methods, Elucid Bio Announces
Dr. Brajesh Lal of the University of Maryland Presents Study Data at the Society for Vascular Surgery Conference July 01, 2020 08:30 AM Eastern Daylight Time BOSTON–(BUSINESS WIRE)–Elucid Bio, maker of the FDA-cleared and CE-marked vascuCAP® software, announced today that […]